Ausgabe 1/2020
Inhalt (16 Artikel)
Reactive oxygen species in cancer: a paradox between pro- and anti-tumour activities
Romina Kohan, Alejandro Collin, Solange Guizzardi, Nori Tolosa de Talamoni, Gabriela Picotto
Validation of an online tool for early prediction of the failure-risk in gestational trophoblastic neoplasia patients treated with methotrexate
Kathleen Dekeister, Pierre-Adrien Bolze, Michel Tod, Rémi Tod, Jérôme Massardier, Jean-Pierre Lotz, Touria Hajri, Olivier Colomban, Michael J. Seckl, Ray Osborne, Gilles Freyer, François Golfier, Benoit You
Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia
Rikke Hebo Larsen, Lisa Lyngsie Hjalgrim, Kathrine Grell, Kim Kristensen, Line Gerner Pedersen, Emilie Damgaard Brünner, Bodil Als-Nielsen, Kjeld Schmiegelow, Jacob Nersting
YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects
Yongxia Zhu, Zhihao Liu, Yanling Qu, Jun Zeng, Meiqin Yang, Xiaoyi Li, Zhaodi Wang, Junxiang Su, Xueqin Wang, Luoting Yu, Yue Wang
New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine
Xandra García-González, Bartosz Kaczmarczyk, Judith Abarca-Zabalía, Fabienne Thomas, Pilar García-Alfonso, Luis Robles, Vanessa Pachón, Ángeles Vaz, Sara Salvador-Martín, María Sanjurjo-Sáez, Luis A. López-Fernández
Influences of preoperative metformin on immunological factors in early breast cancer
Takahiro Tsukioki, Tadahiko Shien, Takehiro Tanaka, Yoko Suzuki, Yukiko Kajihara, Minami Hatono, Kengo Kawada, Mariko Kochi, Takayuki Iwamoto, Hirokuni Ikeda, Naruto Taira, Hiroyoshi Doihara, Shinichi Toyooka
Comparison between single-agent and combination chemotherapy as second-line treatment for advanced non-small cell lung cancer: a multi-institutional retrospective analysis
Yanjiao Yi, Zining Liu, Lihua Fang, Jianzhong Li, Wenjian Liu, Fuxia Wang, Ping Fu, Chao Xie, Jie Liu, Bao Song
C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma
Go Noguchi, Noboru Nakaigawa, Susumu Umemoto, Kota Kobayashi, Yosuke Shibata, Sohgo Tsutsumi, Masato Yasui, Shinji Ohtake, Takahisa Suzuki, Kimito Osaka, Kentaro Muraoka, Hisashi Hasumi, Keiichi Kondo, Yuka Igarashi, Tetsuro Sasada, Takeshi Kishida, Masahiro Yao
Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach
Ken Ogasawara, Patricia M. LoRusso, Anthony J. Olszanski, Olivier Rixe, Christine Xu, Jian Yin, Maria Palmisano, Gopal Krishna
Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
Mats Någård, Mei-Lin Ah-See, Karen So, Marit Vermunt, Fiona Thistlethwaite, Mariette Labots, Patricia Roxburgh, Alain Ravaud, Mario Campone, Liselot Valkenburg-van Iersel, Lone Ottesen, Yan Li, Ganesh Mugundu
First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer
Hossein Taghizadeh, Matthias Unseld, Andreas Schmiderer, Angela Djanani, Klaus Wilthoner, Dieter Buchinger, Gerald W. Prager
A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703)
Shin-ichi Fukumoto, Satoshi Oizumi, Masao Harada, Noriaki Sukoh, Kosuke Nakano, Satoshi Fuke, Jun Sakakibara-Konishi, Kei Takamura, Kenichiro Ito, Yuka Fujita, Yutaka Nishigaki, Toshiyuki Harada, Kenji Akie, Ichiro Kinoshita, Toraji Amano, Hiroshi Isobe, Hirotoshi Dosaka-Akita, Masaharu Nishimura
Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study
Satoshi Noda, Daiki Hira, Rie Osaki, Takehide Fujimoto, Hiroya Iida, Sachiko Tanaka-Mizuno, Akira Andoh, Masaji Tani, Yoshito Ikeda, Shin-ya Morita, Tomohiro Terada
Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX study
Loek A. W. de Jong, Fortuné M. K. Elekonawo, Marie Lambert, Jan Marie de Gooyer, Henk M. W. Verheul, David M. Burger, Johannes H. W. de Wilt, Etienne Chatelut, Rob ter Heine, Philip R. de Reuver, Andre J. A. Bremers, Nielka P. van Erp
Berberine chloride suppresses non-small cell lung cancer by deregulating Sin3A/TOP2B pathway in vitro and in vivo
Jian Chen, Xiaofei Huang, Cheng Tao, Li Wang, Zide Chen, Xinping Li, Qiang Zeng, Min Ma, Ren Zhang, Zhengzhi Wu
Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization
R. B. Verheijen, E. L. Swart, J. H. Beijnen, J. H. M. Schellens, A. D. R. Huitema, N. Steeghs